A meta-analysis of 35 published trials by Leong et al. [28] identified 74 SNPs suggested to be related to cancer-therapy-induced hypertension, decrease in LVEF, and venous thromboembolism, and one in particular (HER2 codon 655 allele rs1136201) to augmenting the risk of trastuzumab-induced cardiotoxicity, as also demonstrated by a previous meta-analysis by the same group [21,28]. This evidence concerns the gene ERBB2 and hypertensive disorder.